IMMIX BIOPHARMA INC (IMMX)
US45258H1068 - Common Stock
Immix Biopharma Announces Positive U.S. Clinical Data From First Four Patients in NEXICART-2 U.S. Trial of sterically-optimized CAR-T NXC-201 in relapsed/refractory Light Chain (AL) Amyloidosis
All four patients treated with NXC-201 normalized their disease markers within 30 days of dosing, of which, two are already classified as complete...
Journal of Clinical Oncology Publishes NXC-201 Positive Clinical Results in relapsed/refractory AL Amyloidosis
Journal of Clinical Oncology Publishes NXC-201 Positive Clinical Results in relapsed/refractory AL Amyloidosis
Chimeric antigen receptor T-cell (CAR-T) cell therapy NXC-201 is a novel approach to treat relapsed/refractory AL Amyloidosis NXC-201 demonstrated...
Immix Biopharma Announces 75% Complete Response Rate (n=16); 31.5 months Best Response Duration (ongoing) for CAR-T NXC-201 in Relapsed/Refractory AL Amyloidosis Patients at ASH 2024
75% (12/16) complete response (CR) rate observed in standard of care (Dara-CyBorD) relapsed/refractory AL Amyloidosis patients with median 4 lines of...
Immix Biopharma to Host Conference Call for Investors, Analysts and Members of the Media
Immix Biopharma to Host Conference Call for Investors, Analysts and Members of the Media
- Company management will provide an update on positive new developments regarding CAR-T NXC-201 in relapsed/refractory AL Amyloidosis. Following...
Immix Biopharma Presents Positive NXC-201 Clinical Data at 66th American Society of Hematology (ASH) Annual Meeting in 16 Relapsed/Refractory AL Amyloidosis Patients
75% (12/16) complete response rate observed in relapsed/refractory AL Amyloidosis patients with median 4 prior lines of therapy Data will be presented...
Immix Biopharma Advances CAR-T NXC-201 to Expansion Cohort Dose Level in U.S. AL Amyloidosis Trial NEXICART-2
Immix Biopharma Advances CAR-T NXC-201 to Expansion Cohort Dose Level in U.S. AL Amyloidosis Trial NEXICART-2
Now dosing at dose expansion level of 450 million NXC-201 CAR+T cells. First cohort at 150 million CAR+T cells already successfully completed Each...
Immix Biopharma Announces Dr. Raymond Comenzo, Internationally Recognized AL Amyloidosis Expert, Director of the Myeloma and Amyloid Program at Tufts Medical Center, Joins Scientific Advisory Board
Dr. Comenzo was the senior author of the landmark Andromeda trial results published in the New England Journal of Medicine in 2021, resulting in...
Immix Biopharma Expands U.S. Clinical Sites for relapsed/refractory AL Amyloidosis Trial NEXICART-2
Immix Biopharma Expands U.S. Clinical Sites for relapsed/refractory AL Amyloidosis Trial NEXICART-2
New Sites Expand Opportunities for Patient Access and Enrollment Clinical Trial Sites Added Include Cleveland Clinic, UC Davis, and Sutter Health...
IMMX Stock Earnings: Immix Biopharma Beats EPS for Q2 2024
IMMX stock results show that Immix Biopharma beat analyst estimates for earnings per share the second quarter of 2024.
IMMX Stock Earnings: Immix Biopharma Beats EPS for Q2 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Immix Biopharma (NASDAQ:IMMX) just reported results for the second quarter of 2...
California Institute for Regenerative Medicine Awards Funding for CAR-T NXC-201 U.S. AL Amyloidosis Clinical Trial (NEXICART-2)
$8 million grant funds development of NXC-201 in relapsed/refractory AL Amyloidosis...
Immix Biopharma Doses 1st Patient in U.S. AL Amyloidosis Trial with CAR-T NXC-201
Immix Biopharma Doses 1st Patient in U.S. AL Amyloidosis Trial with CAR-T NXC-201
Lead site Memorial Sloan Kettering Cancer Center (MSKCC)Timing of milestone in-line with mid-2024 guidanceData from ex-US clinical trial reported at ASGCT...
Immix Biopharma to Present at the Stifel 2024 Cell Therapy Forum
Immix Biopharma to Present at the Stifel 2024 Cell Therapy Forum
LOS ANGELES, June 17, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or “IMMX”), a clinical-stage biopharmaceutical...
IMMX Stock Earnings: Immix Biopharma Beats EPS for Q1 2024
IMMX stock results show that Immix Biopharma beat analyst estimates for earnings per share the first quarter of 2024.
Immix Biopharma Announces Positive NXC-201 Relapsed/Refractory AL Amyloidosis Clinical Data in ASGCT 2024 Late Breaking Oral Presentation
92% (12/13) overall response rate (ORR) for relapsed/refractory AL Amyloidosis patients enrolled in NEXICART-1: 12 out of 12 patients not exposed to prior...
Immix Biopharma Awarded European Union Orphan Drug Designation for NXC-201 in Multiple Myeloma
Immix Biopharma Awarded European Union Orphan Drug Designation for NXC-201 in Multiple Myeloma
European Orphan Drug Designation (“ODD”) qualifies NXC-201 for: 10 years of market exclusivity once authorized in the EUAccess to the EU centralized...
Immix Biopharma on Track to Dose NXC-201 Patients in United States
Immix Biopharma on Track to Dose NXC-201 Patients in United States
Scheduling U.S. site initiation visits April and May 2024On track to dose relapsed/refractory AL Amyloidosis patients with CAR-T NXC-201 at New...
Immix Biopharma Announces Late-Breaking NXC-201 Clinical Data Abstract Accepted for Oral Presentation at the 27th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)
Updated clinical data for next-generation CAR-T NXC-201 in relapsed/refractory AL amyloidosis will be presented in Baltimore May 7-11, 2024 LOS ANGELES,...
IMMX Stock Earnings: Immix Biopharma Misses EPS for Q4 2023
IMMX stock results show that Immix Biopharma missed analyst estimates for earnings per share the fourth quarter of 2023.
IMMX Stock Earnings: Immix Biopharma Misses EPS for Q4 2023
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Immix Biopharma (NASDAQ:IMMX) just reported results for the fourth quarter of 2...
Immix Biopharma Announces Major Comprehensive Cancer Center as Lead Site for NXC-201 AL Amyloidosis Clinical Trial
Immix Biopharma Announces Major Comprehensive Cancer Center as Lead Site for NXC-201 AL Amyloidosis Clinical Trial
LOS ANGELES, CA, March 20, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio”, “Company”, “We” or “Us” or “IMMX”), a...
Immix Biopharma Announces “Be Proactive in AL” AL Amyloidosis Awareness Initiative
Hear from the ~30,000 relapsed or refractory AL Amyloidosis patients in the United States today in their own words
Immix Biopharma Announces “Be Proactive in AL” AL Amyloidosis Awareness Initiative
Hear from the ~30,000 relapsed or refractory AL Amyloidosis patients in the United States today in their own words...
Immix Biopharma 12 Month Review Progress Update
LOS ANGELES, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (Nasdaq: IMMX), a clinical-stage biopharmaceutical company trailblazing cell...
Immix Biopharma Announces Closing of $15 Million Public Offering of Common Stock
Immix Biopharma Announces Closing of $15 Million Public Offering of Common Stock
LOS ANGELES, CA, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or “IMMX”), a clinical-stage...
Immix Biopharma Awarded European Union Orphan Drug Designation for NXC-201 in AL Amyloidosis
European Orphan Drug Designation (“ODD”) qualifies NXC-201 for: 10 years of market exclusivity once authorized in the EUAccess to the EU centralized...